AI’s New Role in Measuring Pain
▼ Summary
– PainChek is an AI-powered mobile app that assesses pain through facial scans and has been approved in Australia, the UK, Canada, and New Zealand, with FDA approval pending in the US.
– Adoption of PainChek in care homes has led to reduced antipsychotic use, fewer falls, and improved resident well-being, such as increased eating and socializing.
– The app speeds up pain assessment to under five minutes, compared to traditional methods, but faces resistance from some staff who prefer clinical judgment or dislike added technology.
– PainChek Infant is being developed for babies under one year, using a specialized algorithm to detect pain in neonatal faces and is undergoing limited testing in Australia.
– Critics raise concerns about potential biases, misreading of facial expressions, over-reliance on the tool, and data entry errors, though proponents see value in objective pain measurement.
Artificial intelligence is now stepping into the critical role of pain assessment, offering a data-driven alternative to subjective evaluations. In Australia, the mobile application PainChek received regulatory clearance in 2017. Government funding subsequently supported its integration into hundreds of aged care facilities across the nation. The system has also gained authorization in the United Kingdom, Canada, and New Zealand, where pilot programs are currently active. In the United States, the technology awaits a decision from the Food and Drug Administration. According to company data, facilities using the tool report impressive outcomes, including a 25% decrease in antipsychotic medication use and a 42% reduction in resident falls in Scotland.
The technology functions by using a smartphone’s camera to scan an individual’s face. An AI algorithm then analyzes the facial expressions to generate a pain score. This provides a standardized, numerical measure for a sensation that is notoriously difficult to quantify.
One early adopter, Orchard Care Homes, found the system transformative. Prior to its implementation, pain assessment was often a box-ticking exercise performed mainly for compliance. Integrating the AI algorithm into their existing workflow yielded significant benefits. An internal study across four care homes monitored monthly pain scores, behavioral incidents, and prescription rates. Within a matter of weeks, the use of psychotropic drugs declined and residents exhibited calmer behavior. The positive effects extended beyond medication logs. Staff noted that residents who had previously refused meals due to undetected dental pain began eating regularly again. Individuals who had become withdrawn started engaging socially.
This technological shift is fostering a cultural change within care environments. During staff training, the importance of objective pain measurement was emphasized by comparing it to vital signs like blood pressure, metrics no one would simply guess. However, achieving full staff buy-in remains challenging. Some experienced nurses are confident in their own clinical judgment, while others are hesitant to adopt another digital tool that requires logging in and creates an audit trail. The broader care sector has been traditionally slow to embrace new technology, but this is gradually changing. The efficiency of the AI system is a compelling argument; a traditional pain scale assessment can take twenty minutes, whereas a PainChek scan and checklist require less than five.
Development is now advancing to serve the most vulnerable patients. Engineers are adapting the software for infants under one year old. Dubbed PainChek Infant, this version addresses the challenge of capturing the rapid, fleeting grimaces of babies. The underlying algorithm has been retrained on neonatal facial expressions, enabling it to detect six specific facial action units based on an established scientific coding system. Limited testing for the infant version is beginning in Australia as the company navigates a separate regulatory approval process.
Despite its promise, the technology is not without its critics. Skeptics point to several potential pitfalls. Facial-analysis AI has a documented history of performance bias related to skin tone. The software might also misinterpret expressions caused by nausea or fear as indicators of pain. The accuracy of the tool is heavily dependent on the yes-or-no answers provided by the caregiver after the scan; careless data entry can easily distort the results. Furthermore, the numerical score lacks the rich, contextual understanding that a caregiver develops through regular interaction and knowledge of a patient’s full medical history. There is also a concern that clinicians might become over-reliant on the algorithm, potentially undermining their own professional judgment.
If the FDA grants approval, PainChek will join a growing field of novel pain measurement technologies. Other startups are developing EEG headbands for nerve pain, skin sensors that detect sudden cancer-related pain flares, and language models that analyze nursing notes for signs of unexpressed distress. Nevertheless, the practice of quantifying pain with an external device carries inherent risks, including potential inaccuracies and embedded biases that may only become apparent after widespread, long-term use.
For many advocates, the potential benefits are clear. One professional shared a personal perspective, stating, “As someone who lives with chronic pain, I’ve often struggled to be believed. A tool like this would have made a tremendous difference.” If artificial intelligence can provide a numerical voice for those who suffer in silence and compel clinicians to listen, then adding a pain score to the standard vital signs chart could very well be worth the effort.
(Source: Technology Review)
